Skip to main content
. 2024 Sep 15;14(9):4459–4471. doi: 10.62347/CWOS3653

Figure 3.

Figure 3

Nomogram model construction and internal validation. A. Nomogram for predicting the progression to CRPC in patients with osseous metastatic PCa and HTB; B. ROC analysis for Nomogram in predicting the 1-year and 2-year risk of progression to CRPC in patients with HTB and osseous metastatic PCa; C. Decision curve analysis for Nomogram in predicting 1-year risk of progression to CRPC in patients HTB and osseous metastatic PCa; D. Decision curve analysis for evaluating the 2-year risk of progression to CRPC in patients with HTB and osseous metastatic PCa; E. Calibrated curves of the Nomogram model for predicting the probability of progression to CRPC at 1 and 2 years versus the actual observed progression probability in patients with high-tumor burden and bone metastatic PCa. Note: PCa: Prostate cancer, HTB: high tumor burden, CRPC: castration-resistant prostate cancer, DCA: decision curve analysis.